|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01875 TOT BIOPHARM-B
Nominal 
1.700 -0.100 (-5.556%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 780,629 | 76.542% | 442,178 | 76,325 | 22,491 | 45,308 |
| Cost of Sales | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (11,481) | 1823.116% | (597) | -- | -- | (29,085) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (2,495) | -62.385% | (6,633) | (17) | 0 | 0 | |
| Profit / (Loss) before Taxation | (37,756) | -24.557% | (50,046) | (261,216) | (288,498) | (299,300) | |
| Taxation | (1) | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 130 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (37,757) | -24.359% | (49,916) | (261,216) | (288,498) | (299,300) | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 2,201 | -49.251% | 4,337 | 1,499 | (174) | 611 |
| Depreciation & Amortisation | 43,028 | 13.115% | 38,039 | 34,237 | 32,082 | 27,351 |
| Directors' Emoluments | 8,974 | 7.242% | 8,368 | 7,196 | 7,683 | 8,945 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -5.000 | -37.500% | -8.000 | -46.000 | -51.000 | -89.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | 0.078 | -- | 0.094 | (0.305) | (0.461) | (0.749) |
| NBV per share ($) | 0.889 | -- | 0.924 | 0.545 | 0.970 | 1.506 |
| Remarks: | Real time quote last updated: 05/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 31,559,000 |
| %Change | -- |
| EPS / (LPS) | RMB 0.040 |
| NBV Per Share (¥) | RMB 0.937 |